The Journal of Allergy and Clinical Immunology: In Practice
Volume 10, Issue 9, September 2022, Pages 2310-2311
EditorialShort-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: Analysis of the Recently Reported Findings From the European and North American SABINA Datasets
References (10)
- et al.
Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study
Lancet
(2017) - et al.
2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group
J Allergy Clin Immunol
(2020) - et al.
Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects
J Allergy Clin Immunol
(2005) - et al.
Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study
Respir Med
(2004) - et al.
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Lancet
(2003)
There are more references available in the full text version of this article.
Cited by (0)
No funding was received for this work.
Conflicts of interest: D.E.S. Larenas-Linnemann reports personal fees from ALK, Allakos, Amstrong, Astrazeneca national and global, Chiesi, DBV Technologies, Grunenthal, GSK national and global, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, and Carnot; and grants from Sanofi, Astrazeneca, Lilly, Pfizer, Novartis, Circassia, UCB, GSK, and Purina Institute, outside the submitted work.
© 2022 American Academy of Allergy, Asthma & Immunology